Membership Directory

SmartCells, Inc.

Category: Drug Development
Phone: 978-927-4246
Fax: 978-405-5700
Website: http://www.smartinsulin.com

SmartCells, Inc. is developing SmartInsulin™, the first glucose-regulated, subcutaneously injectable insulin formulation for treating Type 1 and Type 2 diabetes. It is intended as a drop-in replacement for the injectable insulins currently used by diabetics and addresses their most important challenge - achieving tight blood glucose control without the danger of hypoglycemia. SmartInsulin is a gel that dissolves from the surface inward, releasing insulin only when the surrounding glucose concentration exceeds a specific level. Once the concentration has been reduced below that level, dissolution ceases and the gel is ready for the next glucose challenge. SmartInsulin proof-of-concept studies in hundreds of diabetic rats have demonstrated up to seven days of glucose control and no hypoglycemia with a single subcutaneous injection. Pilot safety and efficacy studies have been completed in pigs and cats. SmartCells has funded operations with $4.8M in NIH/DoD grants and $3.6M in private investment.

Back to list

Recent Jobs